Drug intelligence / Profile preview

Sibosan

Development stage: Unknown
Lead developer: Laves-Arzneimittel
Modality: Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Sibosan is a naturopathic dietary supplement developed by Laves-Arzneimittel GmbH, designed to support intestinal health and the immune system. It is primarily indicated for the regulation of intestinal flora, particularly in cases of small intestinal bacterial overgrowth (SIBO), bloating, and digestive discomfort. The formulation is a combination of the probiotic bacterial strain *Bacillus subtilis* DE111™, the antimicrobial enzyme lysozyme, and a blend of essential oils including eugenol, carvacrol, and thymol. These ingredients work together to restore the natural balance of the gut microbiome and support the body's immune defenses within the gastrointestinal tract. Sibosan is available as vegetarian capsules and is marketed in Germany as a dietary supplement.

Brand names: Sibosan

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on Sibosan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sibosan.

Explore the full profile